On November 9, Iovance Biotherapeutics, Inc. rose 8.52% in Regular Trading, trading at $8.7577/share, with turnover of $28.6836 million.
The move followed a recent quarterly report that beat expectations on both earnings and revenue, prompting the market to refocus on the company’s commercialization progress.
For the quarter ended September 30, the company reported a loss of $0.05 per share, better than consensus expectations of a $0.08 to $0.09 loss, while revenue reached $121.5 million versus expectations of about $116 million. Revenue also increased from $67.5 million a year earlier, indicating continued product uptake and a narrowing loss profile. However, the company maintained full-year product revenue guidance at $410 million to $420 million, rather than raising it again after the sizable increase announced in late September. The latest rise suggests investors are reacting positively to the earnings beat itself despite a more measured view on additional near-term guidance upside.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments